Blackthorn Therapeutics Stock

blackthornrx.comHealthcareFounded: 2015Funding to Date: $130.3MM

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders.

Register for Details

For more details on financing and valuation for Blackthorn Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Blackthorn Therapeutics.

Register Today


Management Team

Edward Roberts Ph.D
Scientific Co-Founder
Paul Berns
Executive Chairman
William Martin Ph.D
Co-Founder, President, Chief Executive Officer & Board Member
Jane Tiller MD
Chief Medical Officer
Monique Levy
Chief Strategy Officer
Hugh Rosen Ph.D
Scientific Co-Founder

Board Members

John MacPhee
Julie Sunderland
Biomatics Capital
Matthew Fust
William Martin Ph.D
Brian Chee
Polaris Partners
Lori Hu
Vertex Ventures HC
Asish Xavier Ph.D
Johnson & Johnson Innovation - JJDC
Kristina Burow
ARCH Venture Partners
Paul Berns

Other companies like Blackthorn Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


BlackThorn Therapeutics, Inc., today announced the promotion of company co-founder and seasoned CNS drug discovery and development expert, William J.
There are numerous challenges to finding effective treatments for mental disorders. However, BlackThorn Therapeutics, a neurobehavioral health company using machine learning to create personalized medicine for mental health, is betting its technological approach to finding drugs that work will put …